Genetically Modified T Cells and Decitabine in Treating Patients With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Roswell Park Cancer Institute
Roswell Park Cancer Institute
First Affiliated Hospital of Zhejiang University
Fudan University
Andes Biotechnologies
Celgene